Editor's Note: The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, showcasing numerous cutting-edge advances. Among the presentations, two prostate cancer studies led by the Department of Urology at Fudan University Shanghai Cancer Center were selected for poster presentation.

The Phase I HDM2005 clinical study (2236P) reported preliminary safety and antitumor activity data for a ROR1-targeted antibody-drug conjugate (ADC) in patients with metastatic castration-resistant prostate cancer (mCRPC). The second study evaluated the HRD Complete tissue-based next-generation sequencing (NGS) companion diagnostic kit, assessing its analytical performance and clinical validity in identifying patients with BRCA1/2-mutated metastatic prostate cancer who may benefit from niraparib plus abiraterone and prednisone. These findings provide important evidence supporting the clinical implementation of homologous recombination repair (HRR) gene testing in prostate cancer. In this issue, we invited Professor Xiaolin Lu of Fudan University Shanghai Cancer Center to share his insights.

01

Led by Fudan University Shanghai Cancer Center, China’s Homegrown ROR1 ADC HDM2005 Makes Its ESMO Poster Debut, Offering New Hope for Heavily Pretreated Patients with mCRPC

Study Background

Following treatment with androgen-axis inhibitors and taxane-based chemotherapy, patients with mCRPC have limited treatment options in later lines of therapy and generally poor prognoses, representing a substantial unmet clinical need.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is highly expressed in prostate cancer tissues and is closely associated with tumor progression, while its expression in normal tissues is low, making it a promising target for ADC therapy. HDM2005 is a domestically developed ROR1-targeted ADC, with monomethyl auristatin E (MMAE) as its payload. At this year’s ESMO Congress, the first results from its Phase I, multicenter, open-label study in patients with mCRPC were presented.

Study Results

Baseline Characteristics

As of March 25, 2026, a total of 17 patients with mCRPC had received at least one dose of HDM2005. Their baseline characteristics were as follows: median age, 70 years (range, 56–77); ECOG performance status (PS) of 0 in 35.3% and 1 in 64.7%. The median number of prior lines of treatment was 5 (range, 1–7), and 94.1% of patients had received at least three lines of systemic therapy, representing a heavily pretreated population.

All patients had distant metastases: bone metastases in 70.6%, liver metastases in 41.2%, lymph node metastases in 35.3%, and lung metastases in 23.5%. The median baseline prostate-specific antigen (PSA) level was 30.6 ng/mL (range, 0.0169–2503.27 ng/mL). In short, most enrolled patients had already experienced failure of multiple standard treatment regimens and had very limited therapeutic options.

Safety Analysis

Overall, the safety profile was manageable, and no dose-limiting toxicities (DLTs) were observed during the study. All participants experienced treatment-emergent adverse events (TEAEs; 100%). Treatment-related serious adverse events (SAEs) occurred in 41.2% (7/17) of patients; 29.4% (5/17) required dose reductions due to TEAEs, while 58.8% (10/17) experienced dose interruptions. No patients permanently discontinued treatment due to TEAEs, and no treatment-related deaths occurred.

The incidence of Grade 3 or higher TEAEs was 64.7%, primarily hematological toxicities, including decreased neutrophil count (41%) and decreased white blood cell count (12%). Most events were manageable and resolved with supportive treatment. Peripheral neuropathy was uncommon, and Grade 3 or higher peripheral neurotoxicity was rare.

Preliminary Antitumor Activity

Among the RECIST-evaluable population (n=10), 3 patients achieved a partial response (PR), including 1 confirmed PR, while 5 patients achieved stable disease (SD). Tumor shrinkage in target lesions was also observed in 3 of the patients with SD. The objective response rate (ORR) was 30.0%, and the disease control rate (DCR) was 80.0%.

In the PSA-evaluable population (n=16, with both baseline and follow-up PSA measurements), 75.0% (12/16) of patients experienced a decline in PSA from baseline. A PSA decline of at least 30% was observed in 37.5% of patients, while the PSA50 response rate—a PSA decline of at least 50%—reached 25.0% (4/16).

The median follow-up was 2.5 months. At the data cutoff, most patients remained on treatment. The longest treatment duration approached 200 days, with the patient still continuing therapy.

Investigator Commentary

In this heavily pretreated, multiple-line mCRPC population, HDM2005 monotherapy demonstrated an overall manageable safety profile. The main Grade 3 or higher adverse events were manageable hematological toxicities, with no treatment-related deaths or permanent treatment discontinuations. Early data also revealed encouraging antitumor activity: the DCR by RECIST assessment reached 80%, and 75.0% of participants experienced a decline in PSA, demonstrating the therapeutic potential of ROR1-targeted ADCs in mCRPC.

The dose-expansion cohorts are currently enrolling. Further studies will confirm the efficacy and safety of HDM2005 and explore the optimal dosing regimen.

For patients with mCRPC in later lines of treatment, ADCs represent an important area of current investigation in genitourinary oncology. The ROR1 target opens up an entirely new avenue for precision treatment in prostate cancer and warrants continued attention from colleagues in urology and medical oncology.

02

Clinical Validation of a Tissue-Based NGS Companion Diagnostic Kit: Supporting Precision Patient Selection in BRCA-Mutated Prostate Cancer

Study Background

Alterations in homologous recombination repair (HRR) genes are important biomarkers in metastatic prostate cancer. Patients with BRCA1/2 mutations can derive significant benefit from PARP inhibitor therapy combined with abiraterone.

The Phase III MAGNITUDE study demonstrated that niraparib combined with abiraterone plus prednisone significantly improved radiographic progression-free survival (rPFS) in patients with HRR-mutated metastatic prostate cancer. In clinical practice, reliable companion diagnostic (CDx) tools are a prerequisite for accurately identifying patients who may benefit from treatment and guiding clinical decision-making.

HRD Complete is an NGS-based testing kit designed for tissue samples. It can detect BRCA1/2 alterations in prostate cancer, including single-nucleotide variants, insertions and deletions, and homozygous deletions. This validation study compared HRD Complete with the clinical trial assay (CTA) used for patient enrollment in MAGNITUDE to evaluate testing concordance. It also assessed the real-world clinical efficacy of the combination regimen in patients identified as BRCA1/2-positive by the kit.

Study Methods

Residual tissue DNA samples from BRCA-positive patients enrolled in the MAGNITUDE study were retrospectively retested using the HRD Complete kit. Samples classified as HRR-negative by the CTA in the PREVALENCE study were also included to evaluate negative percent agreement (NPA).

The primary endpoints were positive percent agreement (PPA), NPA, and overall percent agreement (OPA) between HRD Complete and the clinical trial assay (CTA).

For the clinical efficacy assessment, patients identified as BRCA1/2-positive by HRD Complete were evaluated for rPFS with niraparib plus abiraterone and prednisone versus placebo plus abiraterone and prednisone. The results were compared with those from the original BRCA-positive subgroup in MAGNITUDE.

Study Results

Concordance of Test Results

A total of 208 samples were included in the concordance analysis.

Comparison of HRD Complete with all CTA results (including tissue- and plasma-based testing):

  • Positive percent agreement (PPA): 82.6% (95% CI, 74.7–88.9%)
  • Negative percent agreement (NPA): 98.9% (95% CI, 93.8–100%)
  • Overall percent agreement (OPA): 89.4% (95% CI, 84.4–93.3%)

Since HRD Complete is a tissue-based testing kit, a further paired comparison was conducted against tissue-based CTA results alone, involving 205 samples. Concordance improved further:

  • Positive percent agreement (PPA): 91.7% (95% CI, 84.8–96.1%)
  • Negative percent agreement (NPA): 99.0% (95% CI, 94.4–100%)
  • Overall percent agreement (OPA): 95.1% (95% CI, 91.2–97.6%)

These findings indicate a high level of agreement between the HRD Complete tissue-based kit and the original tissue-based clinical trial assay, with NPA approaching 100%, suggesting a very low risk of false-negative results.

Clinical Efficacy Validation

Among patients identified as BRCA1/2-positive by HRD Complete, niraparib plus abiraterone and prednisone versus placebo plus abiraterone and prednisone resulted in an rPFS hazard ratio (HR) of 0.549 (95% CI, 0.297–1.017; P=0.0534), corresponding to a 45% reduction in the risk of radiographic progression or death.

This result was highly consistent with the efficacy observed in the original BRCA-positive subgroup selected by the CTA in MAGNITUDE (original subgroup HR=0.533; P=0.0014).

Regarding survival outcomes, the median rPFS in the HRD Complete-positive cohort was 18.43 months in the combination therapy group, compared with 11.17 months in the control group. The trend in benefit was consistent with that observed in the original study. The 6-, 12-, and 18-month event-free survival rates were also comparable to those reported in the original BRCA-positive MAGNITUDE population.

Investigator Commentary

The HRD Complete tissue-based NGS kit demonstrated high concordance with the tissue-based reference assay used in the clinical trial, with negative percent agreement for BRCA1/2 mutations approaching 99%. It can therefore be used to identify BRCA1/2 mutations in patients with metastatic prostate cancer.

Patients identified as BRCA1/2-mutated by HRD Complete achieved an rPFS benefit with niraparib plus abiraterone comparable to that observed in the original BRCA-positive population in MAGNITUDE, confirming the clinical validity of the kit.

In the era of precision prostate cancer diagnosis and treatment, reliable companion diagnostics are essential to implementing PARP inhibitor-based combination therapy in clinical practice. This CDx validation study provides important clinical evidence supporting the use of tissue-based NGS testing to identify prostate cancer patients who may benefit from treatment, and offers valuable guidance for clinical practice in urology and medical oncology in China.